| Title |
Publication Date |
Price |
Relevance |
Apoptosis in Oncology
Drug Pipeline Update 2009
|
January 2009 |
£1285 |
98 % |
Analytical Tool: Apoptosis
Promise or deception?
|
May 2007 |
£2660 |
97 % |
Analytical Tool - Apoptosis in Oncology
|
January 2009 |
£2660 |
96 % |
Competitive Outlook on Apoptosis in Oncology
|
December 2006 |
£1670 |
96 % |
Apoptosis: Industry Background Report
List of Companies
|
October 2005 |
£345 |
96 % |
Triple Analysis: Apoptosis Agents, Antibodies and Vaccines in Oncology
|
December 2006 |
£2960 |
93 % |
Triple Analysis: Apoptosis Agents, Protein Kinase Inhibitors and Anti-Angiogenic Agents in Oncology
|
December 2006 |
£4440 |
84 % |
Targeted Therapies in Oncology
|
September 2007 |
£105 |
35 % |
Targeted Therapies in Oncology
|
May 2007 |
£100 |
35 % |
Garner and Klintworth's Pathobiology of Ocular Disease, 3rd edition
|
August 2007 |
£0 |
21.5 % |
Cardiovascular Molecular Imaging
|
July 2007 |
£130 |
19.25 % |
Global Pipeline Review & Analysis of Hematological Malignancies
|
March 2007 |
£2025 |
15.4 % |
PARP Inhibitors
Competitor Analysis
|
April 2009 |
£86 |
14 % |
Targeted Therapeutics in Non-Small Cell Lung Cancer
|
April 2007 |
£1340 |
14 % |
Breast Cancer
Therapeutic And Competitive Insights
|
February 2007 |
£1340 |
13.65 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1680 |
13.65 % |
Hypoxia-Inducible Factor (HIF)
Competitor Analysis
|
April 2009 |
£86 |
13.5 % |
Lymphoma
A Therapeutic & Competitive Insight
|
May 2006 |
£1670 |
12.25 % |
Vasogen Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
12 % |
Neuroprotection
Drugs, Markets and Companies
|
May 2009 |
£2440 |
12 % |
Drug Targets for Breast Cancer
|
January 2006 |
£1095 |
11.9 % |
Antibody Drug Target Atlas in Oncology
|
June 2007 |
£1680 |
11.55 % |
Targeted Therapies in Oncology
A World Review
|
December 2006 |
£4245 |
11.55 % |
Triple Progress Analysis: Melanoma, Colorectal & Lung Cancer
|
March 2006 |
£2960 |
11.55 % |
Analytical Tool - Current & Future Lung Cancer Therapeutics
|
May 2007 |
£2660 |
11.55 % |
Target Atlas in Oncology Drug Development: Targeted Therapies
|
March 2009 |
£3515 |
11 % |
EpiCept Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
11 % |
Triple Target Atlas in Oncology Drug Development
|
March 2009 |
£2660 |
10.5 % |
Complete Target Atlas in Oncology Drug Development: From Tumor to Targeted Therapy
|
March 2009 |
£2660 |
10.5 % |
Novel Mitotic Kinase Inhibitors
Competitor Analysis
|
May 2009 |
£300 |
10.5 % |
Pipeline Insight: Molecular Targeted Cancer Therapies
More pipeline activity, less product differentiation
|
November 2008 |
£8000 |
10.5 % |
Protein Kinase C (PKC) Inhibitors
Competitor Analysis
|
January 2009 |
£170 |
10 % |
Influencing Brand Preferences in the Flow Cytometry Market
|
July 2006 |
£3295 |
10 % |
Molecular Imaging in Drug R&D and Medical Practice
Technologies, Applications, Markets
|
January 2008 |
£685 |
9.8 % |
Prostate and Breast Cancer
New Treatments & Developmental Progress
|
March 2007 |
£2025 |
9.8 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas
|
June 2007 |
£2365 |
9.45 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer
|
June 2007 |
£2365 |
9.45 % |
Monoclonal Antibodies, Vaccines and Other Immunologic Cancer Treatments
World Market
|
May 2007 |
£1215 |
9.45 % |
Emerging Opportunities with Cannabinoids
|
September 2008 |
£795 |
9 % |
Non-Small Cell Lung Cancer Drug Pipeline Update 2007
|
April 2007 |
£1285 |
8.5 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC
|
July 2007 |
£2365 |
8.4 % |
Top 7 Cancer Indications
Therapeutic & Competitive Insights
|
January 2007 |
£5960 |
8.4 % |
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies
More drugs on the market, more targets in the pipeline
|
October 2006 |
£8000 |
8.05 % |
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007
|
June 2007 |
£1999 |
7.7 % |
World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The
|
May 2009 |
£2435 |
7.35 % |
Drug Delivery in Cancer
Technologies, Markets and Companies
|
May 2009 |
£1830 |
7.35 % |
Chemotherapy Market Insights, 2006-2016
A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
|
April 2006 |
£1900 |
7 % |
Rheumatoid Arthritis: Emerging drug discovery targets
And therapeutic candidates
|
October 2003 |
£375 |
6.5 % |
Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies
|
May 2006 |
£2960 |
5.95 % |
Triple Analysis: Protein Kinase Inhibitors, Antibodies and Vaccines in Oncology
|
August 2006 |
£2960 |
5.95 % |
Cancer Cell Therapy Markets
|
March 2008 |
£2075 |
5.6 % |
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents
|
October 2006 |
£2960 |
5.25 % |
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology
|
August 2006 |
£2960 |
4.9 % |
Pipeline Insight: Non-Small Cell Lung Cancer
Pipeline set to offer only modest improvements
|
April 2008 |
£6000 |
4.9 % |
Pipeline Insight: Breast Cancer
Recent approvals increase pressure on pipeline candidates
|
April 2008 |
£6000 |
4.9 % |
Parkinson's Disease Market analysis and forecasts
2008-2012, 2017 & 2022
|
January 2008 |
£1499 |
4.9 % |
Cancer Therapeutics: The Worldwide Market
The Worldwide Market , 2nd Editon
|
February 2007 |
£2435 |
4.9 % |
Clinical Trials Business; The
|
August 2006 |
£2960 |
4.55 % |
Epigenomics
Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics
|
March 2007 |
£2960 |
4.2 % |
Nitric Oxide
Therapeutics, Markets and Companies
|
May 2009 |
£1710 |
4.2 % |
Pipeline Insight: Hematological Malignancies Companies target niche indications to facilitate market entry
|
April 2009 |
£6000 |
3.85 % |
Pipeline Insight: Cancer Overview
Increasing Diversity Offers Both High Risk And Reward
|
September 2007 |
£7600 |
3.5 % |
Personalized Medicine
Scientific & Commercial Aspects
|
May 2009 |
£2440 |
3.15 % |
